4.5 Review

Why and how to spare the hippocampus during brain radiotherapy: the developing role of hippocampal avoidance in cranial radiotherapy

期刊

RADIATION ONCOLOGY
卷 9, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/1748-717X-9-139

关键词

Hippocampus; Hippocampal sparing; Hippocampal avoiding radiotherapy; Brain radiotherapy; Feasibility study; Planning study

资金

  1. European Regional Development Fund - Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]
  2. Czech Researchers Abroad II: Young Talent Incubator [CZ.1.07/2.3.00/20.0117]
  3. MH CZ - DRO (MMCI) [00209805]
  4. Czech Ministry of Health [IGA NT/14600, NT/14120]

向作者/读者索取更多资源

The goal of this review is to summarize the rationale for and feasibility of hippocampal sparing techniques during brain irradiation. Radiotherapy is the most effective non-surgical treatment of brain tumors and with the improvement in overall survival for these patients over the last few decades, there is an effort to minimize potential adverse effects leading to possible worsening in quality of life, especially worsening of neurocognitive function. The hippocampus and associated limbic system have long been known to be important in memory formation and pre-clinical models show loss of hippocampal stem cells with radiation as well as changes in architecture and function of mature neurons. Cognitive outcomes in clinical studies are beginning to provide evidence of cognitive effects associated with hippocampal dose and the cognitive benefits of hippocampal sparing. Numerous feasibility planning studies support the feasibility of using modern radiotherapy systems for hippocampal sparing during brain irradiation. Although results of the ongoing phase II and phase III studies are needed to confirm the benefit of hippocampal sparing brain radiotherapy on neurocognitive function, it is now technically and dosimetrically feasible to create hippocampal sparing treatment plans with appropriate irradiation of target volumes. The purpose of this review is to provide a brief overview of studies that provide a rationale for hippocampal avoidance and provide summary of published feasibility studies in order to help clinicians prepare for clinical usage of these complex and challenging techniques.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Radiology, Nuclear Medicine & Medical Imaging

Contrast-Enhanced Ultrasonography for Differential Diagnosis of Benign and Malignant Thyroid Lesions: Single-Institutional Prospective Study of Qualitative and Quantitative CEUS Characteristics

Hana Petrasova, Radka Slaisova, Tomas Rohan, Karel Stary, Jitka Kyclova, Tomas Pavlik, Petra Kovalcikova, Tomas Kazda, Vlastimil Valek

Summary: This study extends and revises the diagnostic value of CEUS for distinguishing between malignant and benign thyroid nodules. The results show that different enhancement patterns are significantly associated with benign and malignant lesions. Ring enhancement pattern indicates a benign etiology, while heterogeneous enhancement pattern suggests a malignant etiology. The shape of the TIC can also help differentiate between benign and malignant lesions.

CONTRAST MEDIA & MOLECULAR IMAGING (2022)

Article Oncology

Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients

Jana Halamkova, Lucia Bohovicova, Lucie Pehalova, Roman Gonec, Teodor Stanek, Tomas Kazda, Lucie Moukova, Dagmar Adamkova Krakorova, Sarka Kozakova, Marek Svoboda, Regina Demlova, Igor Kiss

Summary: The association between hypolipidemic drugs and the occurrence of a second primary malignancy in colorectal cancer survivors is not clear. Subgroup analysis shows a lower incidence of secondary neoplasia in statin users, but colorectal cancer patients using hypolipidemic drugs are more likely to develop gastric and bladder cancer. Patients with early-stage colorectal carcinoma who suffered a second cancer have significantly worse survival outcomes if treated with hypolipidemic drugs. Therefore, screening for second primary malignancies in colorectal cancer survivors treated with hypolipidemic drugs should be done more cautiously, especially for gastric and bladder cancer.

CANCERS (2022)

Review Oncology

The Significance of MicroRNAs in the Molecular Pathology of Brain Metastases

Frantisek Siegl, Marek Vecera, Ivana Roskova, Martin Smrcka, Radim Jancalek, Tomas Kazda, Ondrej Slaby, Jiri Sana

Summary: The importance of microRNAs in brain metastasis, as well as their potential clinical implications, are summarized in this review. MicroRNAs are small non-coding RNAs that play a crucial role in regulating gene expression and cellular processes. They have been implicated in various cancers, including brain metastases, and show promise as diagnostic molecules and therapeutic targets.

CANCERS (2022)

Article Medicine, General & Internal

Biomarker Dynamics and Long-Term Treatment Outcomes in Breast Cancer Patients with Residual Cancer Burden after Neoadjuvant Therapy

Milos Holanek, Iveta Selingerova, Pavel Fabian, Oldrich Coufal, Ondrej Zapletal, Katarina Petrakova, Tomas Kazda, Roman Hrstka, Alexandr Poprach, Maria Zvarikova, Ondrej Bilek, Marek Svoboda

Summary: This retrospective study suggests that residual cancer burden after neoadjuvant therapy is associated with worse treatment outcomes in breast cancer patients. The study evaluated the dynamics and impact of biomarkers on long-term outcomes in specific breast cancer subtypes. The proliferation index Ki-67 was significantly altered by neoadjuvant therapy and predicted survival outcomes in different subtypes.

DIAGNOSTICS (2022)

Review Health Care Sciences & Services

FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer

Martin Dolezel, Marek Slavik, Tomas Blazek, Tomas Kazda, Pavel Koranda, Lucia Veverkova, Petr Burkon, Jakub Cvek

Summary: Concurrent chemoradiotherapy is commonly used in the curative treatment of head and neck cancer patients, with locoregional failure being the main recurrence pattern. Tumor hypoxia is a major cause of treatment failure, and positron emission tomography (PET) has been extensively studied as a feasible method for detecting tumor hypoxia. Escalating the dose to hypoxic tumors has shown potential to improve outcomes. The optimization of radiotherapeutic plans has been well-documented, and there are two main approaches for defining the hypoxic tumor volume based on PET images.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Review Biochemistry & Molecular Biology

Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer-A Critical Review and Practical Consideration

Petr Burkon, Jan Trna, Marek Slavik, Radim Nemecek, Tomas Kazda, Petr Pospisil, Milan Dastych, Michal Eid, Ivo Novotny, Tomas Prochazka, Miroslav Vrzal

Summary: Pancreatic cancer is the third leading cause of cancer death in the developed world. Surgical resection is the only cure, but for advanced cases, neoadjuvant therapy and stereotactic body radiotherapy (SBRT) may improve treatment outcomes and offer convenience and tolerability.

BIOMEDICINES (2022)

Article Medicine, General & Internal

Spinal Metastasis in a Patient with Supratentorial Glioblastoma with Primitive Neuronal Component: A Case Report with Clinical and Molecular Evaluation

Michal Hendrych, Peter Solar, Marketa Hermanova, Ondrej Slaby, Hana Valekova, Marek Vecera, Alena Kopkova, Zdenek Mackerle, Tomas Kazda, Petr Pospisil, Radek Lakomy, Jan Chrastina, Jiri Sana, Radim Jancalek

Summary: This case report describes a 43-year-old female patient with frontal glioblastoma who developed intraspinal metastasis five months after surgery. Next-generation sequencing analysis revealed a higher number of single nucleotide variants in the metastatic sample compared to the primary tumor. Mutations in NF1, NOTCH3, and ARID1A were identified and may contribute to the invasiveness and metastatic potential of this particular glioblastoma case.

DIAGNOSTICS (2023)

Article Oncology

Effects of Reoperation Timing on Survival among Recurrent Glioblastoma Patients: A Retrospective Multicentric Descriptive Study

Ondrej Kalita, Tomas Kazda, Stefan Reguli, Radim Jancalek, Pavel Fadrus, Marek Slachta, Petr Pospisil, Lukas Krska, Jana Vrbkova, Lumir Hrabalek, Martin Smrcka, Radim Lipina

Summary: The timing of reoperation has a significant impact on the survival rates of patients with recurrent glioblastoma. Reoperation after 16 months from the first surgery has a significant effect on postsurgical survival. After adjusting for age, significant improvement in postsurgical survival was observed for time-to-progression thresholds of 22 and 24 months.

CANCERS (2023)

Editorial Material Clinical Neurology

Financial toxicity of radiotherapy for multiple brain metastases: Will it get worse or better?

Tomas Kazda, Katerina Polachova

NEURO-ONCOLOGY PRACTICE (2023)

Article Oncology

Dosimetric patterns of failure in the era of novel chemoradiotherapy in newly-diagnosed glioblastoma patients

Maasa H. Seaberg, Tomas Kazda, Ryan S. Youland, Nadia N. Laack, Deanna H. Pafundi, S. Keith Anderson, Jann N. Sarkaria, Evanthia Galanis, Paul D. Brown, Debra H. Brinkmann

Summary: This study analyzed the patterns of failure in glioblastoma patients receiving novel chemoradiotherapy regimens and found that the patterns were influenced by the timepoint of analysis and appeared to originate from the central region. Addition of specific chemotherapy drugs may also influence the patterns of failure, although it does not impact overall survival.

RADIOTHERAPY AND ONCOLOGY (2023)

Review Oncology

Primary Breast Sarcoma: A Two-Centre Analysis and Review of Literature

Jan Zatecky, Oldrich Coufal, Pavel Fabian, Milos Holanek, Eva Sehnalkova, Petr Burkon

Summary: This study retrospectively analyzed a case series from two hospitals in the Czech Republic to evaluate the diagnostic and treatment approach to primary breast sarcomas and analyze published prognostic factors. The study included 11 patients, 9 women and 2 men. Statistical evaluation showed that tumor size, grade, margin distance, mitotic activity, or age were not prognostic factors in our cohort. Based on the literature review, the most common published prognostic factors are tumor size, margin status, and grade, but the results are ambiguous.

BREAST CARE (2023)

暂无数据